308 related articles for article (PubMed ID: 38487087)
1. Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment.
Ebrahimnia M; Alavi S; Vaezi H; Karamat Iradmousa M; Haeri A
EXCLI J; 2024; 23():143-179. PubMed ID: 38487087
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic applications of implantable drug delivery systems.
Dash AK; Cudworth GC
J Pharmacol Toxicol Methods; 1998 Jul; 40(1):1-12. PubMed ID: 9920528
[TBL] [Abstract][Full Text] [Related]
3. Recent Progress in Implantable Drug Delivery Systems.
He GQ; Li H; Liu J; Hu YL; Liu Y; Wang ZL; Jiang P
Adv Mater; 2024 Jun; 36(23):e2312530. PubMed ID: 38376369
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Recent Advances in Targeted Drug Delivery for Cancer Pain: Is It Time to Change the Paradigm?
Dupoiron D; Duarte R; Carvajal G; Aubrun F; Eldabe S
Pain Physician; 2022 May; 25(3):E414-E425. PubMed ID: 35652767
[TBL] [Abstract][Full Text] [Related]
5. Solid implantable devices for sustained drug delivery.
Magill E; Demartis S; Gavini E; Permana AD; Thakur RRS; Adrianto MF; Waite D; Glover K; Picco CJ; Korelidou A; Detamornrat U; Vora LK; Li L; Anjani QK; Donnelly RF; Domínguez-Robles J; Larrañeta E
Adv Drug Deliv Rev; 2023 Aug; 199():114950. PubMed ID: 37295560
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management.
Carvajal G
Pain Physician; 2021 Aug; 24(5):E583-E594. PubMed ID: 34323445
[TBL] [Abstract][Full Text] [Related]
7. Designing Hydrogels for On-Demand Therapy.
Oliva N; Conde J; Wang K; Artzi N
Acc Chem Res; 2017 Apr; 50(4):669-679. PubMed ID: 28301139
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Intrathecal Drug Delivery Systems for the Management of Cancer Pain: A Systematic Review and Meta-Analysis.
Duarte R; Copley S; Nevitt S; Maden M; Al-Ali AM; Dupoiron D; Eldabe S
Neuromodulation; 2023 Aug; 26(6):1126-1141. PubMed ID: 35422368
[TBL] [Abstract][Full Text] [Related]
11. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
Smith TJ; Coyne PJ
J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).
Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Cousins M; Pool GE
Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US.
Goel V; Kumar V; Blaes A; Gulati A
Neuromodulation; 2023 Aug; 26(6):1256-1262. PubMed ID: 37318432
[TBL] [Abstract][Full Text] [Related]
16. Progress in the design and development of "fast-dissolving" electrospun nanofibers based drug delivery systems - A systematic review.
Balusamy B; Celebioglu A; Senthamizhan A; Uyar T
J Control Release; 2020 Oct; 326():482-509. PubMed ID: 32721525
[TBL] [Abstract][Full Text] [Related]
17. Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics.
Cong YY; Fan B; Zhang ZY; Li GY
Int Ophthalmol; 2023 Jul; 43(7):2575-2588. PubMed ID: 36715956
[TBL] [Abstract][Full Text] [Related]
18. Applications of Novel and Nanostructured Drug Delivery Systems for the Treatment of Oral Cavity Diseases.
Hosseinpour-Moghadam R; Mehryab F; Torshabi M; Haeri A
Clin Ther; 2021 Dec; 43(12):e377-e402. PubMed ID: 34844769
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Measured Radiotherapy Dose on Intrathecal Drug Delivery System Function.
Odell DW; Albrechtsen RD; Sindt JE; Gole R; Brown S; Parsons MW; Paxton AB; Sarkar V; Lloyd S; Brogan SE; Tao R
Neuromodulation; 2021 Oct; 24(7):1204-1208. PubMed ID: 33624320
[TBL] [Abstract][Full Text] [Related]
20. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
